Mechanism of suramin-induced deoligomerization of tumor necrosis factor alpha.

Deoligomerization of human tumor necrosis factor alpha (TNF), spiked with 125I-labeled form, was studied quantitatively using size-exclusion chromatography and off-line monitoring with a gamma-counter. A detailed investigation of the oligomeric state of TNF was carried out as a function of its own concentration (0.3-7500 nM referred to the subunit, M(r) 17,000) in the absence or in the presence of various amounts (10, 100, 1000 microM) of suramin, an inhibitor of TNF biological activity in vitro, which promotes TNF deoligomerization. The dependence of trimeric form content on total TNF concentration was modeled with a sequential dissociation process (trimer-->dimer-->monomer) assuming an identical dissociation constant for each step, Kd1 = 0.2 nM. This model was used as the simplest for data fitting although, generally, no chromatographic resolution of dimeric species could be obtained. Best fitting of all data could be achieved with a model including a conformational change of TNF trimer into a state more prone to deoligomerization (Kd2 = 400 nM), which was favored by suramin binding. A kinetic study of TNF dissociation by the same method produced values for the deoligomerization rate of trimer: on the average, koff approximately 4 x 10(-5) S-1 (t1/2 approximately 5 h) between 4 and 20 degrees C with little dependence on suramin concentration; at 37 degrees C, a sizable increase is observed in the presence of 1 mM suramin (koff = 2.3 x 10(-4) S-1, t1/2 = 0.8 h). Data of suramin inhibition on TNF receptor binding, as obtained after incubation times much shorter than the above half-life of trimer, indicate that suramin binding to TNF trimer is the early mechanism of receptor binding inhibition.

[1]  A. Corti,et al.  Kinetic analysis of TNF-alpha oligomer-monomer transition by surface plasmon resonance and immunochemical methods. , 1993, Cytokine.

[2]  P Ghezzi,et al.  Suramin induces deoligomerization of human tumor necrosis factor alpha. , 1993, The Journal of biological chemistry.

[3]  D. Volkin,et al.  Nature of the interaction of growth factors with suramin. , 1992, Biochemistry.

[4]  A. Consonni,et al.  Heparin binding to human plasma low-density lipoproteins: dependence on heparin sulfation degree and chain length. , 1992, Biochemistry.

[5]  A. Corti,et al.  Oligomeric tumour necrosis factor α slowly converts into inactive forms at bioactive levels , 1992 .

[6]  F. Marcucci,et al.  Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor alpha. , 1992, International journal of immunopharmacology.

[7]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[8]  L. Rv,et al.  Suramin: prototype of a new generation of antitumor compounds. , 1990 .

[9]  A. Nykjær,et al.  Bioactive human recombinant tumor necrosis factor‐α: an unstable dimer? , 1989 .

[10]  S. Staats,et al.  Reversible subunit dissociation of tumor necrosis factor during hydrophobic interaction chromatography. , 1988, Journal of chromatography.

[11]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[12]  F. Hawking Suramin: with special reference to onchocerciasis. , 1978, Advances in pharmacology and chemotherapy.

[13]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[14]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.